AP-III-a4

AP-III-a4 (ENOblock) is a nonsubstrate analogue enolase inhibitor with an IC50 of 0.576 uM. AP-III-a4 can be used for the research of cancer and diabetic[1].

Product Specifications

CAS Number

[1177827-73-4]

Product Name Alternative

ENOblock

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Enolase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ap-iii-a4.html

Purity

99.87

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC1=CC=C(CNC2=NC(NCC3CCCCC3)=NC(NC4=CC=C(CC(NCCOCCOCCN)=O)C=C4)=N2)C=C1

Molecular Formula

C31H43FN8O3

Molecular Weight

594.72

Precautions

H302, H315, H319, H335

References & Citations

[1]Da-Woon Jung, et al. A Unique Small Molecule Inhibitor of Enolase Clarifies Its Role in Fundamental Biological Processes.ACS Chem. Biol., 2013, 8 (6), pp 1271–1282

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, protect from light)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Biomed Pharmacother. 2024 Jun 18:177:116970.|bioRxiv. 2024 October 25.|Cancer Cell. 2024 Aug 12;42 (8) :1386-1400.e8.|Cancer Res. 2025 Nov 21:10.1158/0008-5472.CAN-24-3753.|Cell Discov. 2020 Aug 18;6:56.|Int J Mol Sci. 2025 Apr 13;26 (8) :3677.|Proc Natl Acad Sci U S A. 2025 May 13;122 (19) :e2415089122.|Research Square Print. November 14th, 2022|SSRN. 2023 Feb 10.|Theranostics. 2019 Aug 12;9 (20) :5769-5783.|Cancers (Basel) . 2020 Jan 29;12 (2) :311.|EMBO Mol Med. 2025 Dec;17 (12) :3496-3524.|Gastroenterology. 2024 Jan 24:S0016-5085 (24) 00064-7.